sorafenib has been researched along with vorinostat in 25 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (vorinostat) | Trials (vorinostat) | Recent Studies (post-2010) (vorinostat) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,529 | 181 | 1,840 |
| Protein | Taxonomy | sorafenib (IC50) | vorinostat (IC50) |
|---|---|---|---|
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Histone deacetylase 8 | Schistosoma mansoni | 1.3147 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Gli1 | Mus musculus (house mouse) | 2.23 | |
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 0.7472 | |
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 1.55 | |
| Histone deacetylase 1 | Mus musculus (house mouse) | 0.1121 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.3382 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.2644 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.0382 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.456 | |
| Tubulin alpha-1A chain | Sus scrofa (pig) | 1.5 | |
| Tubulin beta chain | Sus scrofa (pig) | 1.5 | |
| Albumin | Homo sapiens (human) | 0.1072 | |
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 4.66 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.0903 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.011 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.24 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.1582 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.053 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.116 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Leukotriene A-4 hydrolase | Mus musculus (house mouse) | 6.15 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.042 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.13 | |
| Delta-type opioid receptor | Homo sapiens (human) | 7.2 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 7.2 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.6096 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.086 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.322 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.2701 | |
| Histone deacetylase 1 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.07 | |
| Renin | Macaca fascicularis (crab-eating macaque) | 0.067 | |
| Histone deacetylase 3 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 1 | |
| Histone deacetylase | Plasmodium falciparum 3D7 | 0.1 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6115 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3746 | |
| HD2 type histone deacetylase HDA106 | Zea mays | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.4211 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.5235 | |
| Carboxypeptidase B2 | Homo sapiens (human) | 0.362 | |
| Histone deacetylase 7 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 6 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 4 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.9141 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2634 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5614 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.5926 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0945 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.0905 | |
| Histone deacetylase 6 | Mus musculus (house mouse) | 0.3742 | |
| Histone deacetylase | Zea mays | 0.029 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, D; Goh, WH; Soh, CK; Wang, H | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Chen, SS; Lee, HY; Lee, S; Liu, YT; Tai, HC; Tuan, YL; Wang, HH; Wang, SW; Yen, JY; Yu, CL | 1 |
| Dai, Y; Dasmahapatra, G; Dent, P; Grant, S; Yerram, N | 1 |
| Curiel, DT; Dent, P; Fisher, PB; Graf, M; Grant, S; Hamed, H; Lee, R; Martin, AP; Mitchell, C; Park, MA; Rahmani, M; Roberts, JD; Yacoub, A; Zhang, G | 1 |
| Dent, P; Fisher, PB; Graf, M; Grant, S; Hamed, H; Hylemon, PB; Liu, X; Martin, AP; Mitchell, C; Norris, J; Park, MA; Rahmani, M; Ryan, K; Spiegel, S; Zhang, G | 1 |
| Dent, P; Graf, M; Grant, S; Houghton, PJ; Mitchell, C; Park, MA; Rahmani, M; Voelkel-Johnson, C; Walker, T; Yacoub, A | 1 |
| Allegood, J; Dent, P; Fisher, PB; Grant, S; Häussinger, D; Larner, A; Mitchell, C; Ogretmen, B; Park, MA; Reinehr, R; Spiegel, S; Voelkel-Johnson, C; Yacoub, A; Zhang, G | 1 |
| Dent, P; Grant, S; Häussinger, D; Ogretmen, B; Park, MA; Reinehr, R; Voelkel-Johnson, C; Yacoub, A | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Camidge, DR; Dasari, A; Diab, S; Drabkin, HA; Flaig, TW; Gore, L; Jimeno, A; Lewis, KD; Messersmith, WA; Weekes, CD | 1 |
| Choi, J; Hwang, JJ; Jang, S; Jeong, IG; Kim, CS; Kim, DE; Kim, MJ; Lee, JH; Ro, S | 1 |
| Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE | 1 |
| Cui, LJ; Li, AJ; Ma, SL; Wu, B; Wu, MC; Yin, L; Yuan, H | 1 |
| Blay, JY; Dumont, AG; Dumont, SN; Reynoso, D; Trent, JC; Yang, D | 1 |
| Gülow, K; Kießling, MK; Klemke, CD; Krammer, PH; Nicolay, JP; Schlör, T; Süss, D | 1 |
| Chai, ZT; Jia, QA; Ma, DN; Qin, CD; Ren, ZG; Sun, HC; Tang, ZY; Wang, CH; Zhang, N; Zhang, SZ; Zhu, XD | 1 |
| Booth, L; Dent, P; Poklepovic, A; Roberts, JL | 1 |
| Abu Zaid, M; Boswell, HS; Cripe, LD; Konig, H; Saliba, AN; Sayar, H | 1 |
| Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB | 1 |
| Booth, L; Dent, P; Poklepovic, A | 1 |
| Chan, YT; Feng, Y; Feng, Z; Huang, L; Lan, J; Liu, Y; Lu, Y; Pan, W; Wang, N | 1 |
4 review(s) available for sorafenib and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
3 trial(s) available for sorafenib and vorinostat
| Article | Year |
|---|---|
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2013 |
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; Humans; Hypokalemia; Hypophosphatemia; Liver Neoplasms; Male; Middle Aged; Sorafenib; Thrombocytopenia; Vorinostat | 2019 |
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Survival; Female; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Quinolines; Sorafenib; Vorinostat | 2020 |
18 other study(ies) available for sorafenib and vorinostat
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Molecular Structure; Phenylurea Compounds; Protein Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Topics: Benzenesulfonates; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Tumor Cells, Cultured; Vorinostat | 2007 |
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Death; Cell Line, Tumor; Drug Synergism; fas Receptor; Humans; Hydroxamic Acids; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat | 2008 |
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Caspase 8; Cell Survival; Ceramides; eIF-2 Kinase; Endoplasmic Reticulum; Eukaryotic Initiation Factor-2; fas Receptor; Humans; Hydroxamic Acids; Models, Biological; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vorinostat | 2008 |
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme Activation; HCT116 Cells; Humans; Hydroxamic Acids; JNK Mitogen-Activated Protein Kinases; Membrane Proteins; Niacinamide; Oxidoreductases; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat | 2009 |
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcium; Carboxylic Ester Hydrolases; Cell Line, Tumor; Ceramides; fas Receptor; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Niacinamide; Phenylurea Compounds; Pyridines; Reactive Oxygen Species; Signal Transduction; Sorafenib; Vorinostat | 2010 |
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Topics: Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Fas Ligand Protein; fas Receptor; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Niacinamide; Phenylurea Compounds; Phosphotyrosine; Protein Kinase Inhibitors; Pyridines; Reactive Oxygen Species; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sorafenib; src-Family Kinases; Vorinostat | 2010 |
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Von Hippel-Lindau Tumor Suppressor Protein; Vorinostat | 2012 |
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib; Vorinostat; Xenograft Model Antitumor Assays | 2014 |
Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Transfection; Tumor Suppressor Protein p53; Vorinostat | 2014 |
Targeted polytherapy in small cell sarcoma and its association with doxorubicin.
Topics: Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Doxorubicin; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Sarcoma, Small Cell; Sorafenib; Vorinostat | 2014 |
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; MAP Kinase Signaling System; Membrane Proteins; Molecular Targeted Therapy; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2017 |
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Topics: Animals; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Decitabine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; raf Kinases; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Sorafenib; Vorinostat | 2018 |
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Male; Mice; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2019 |
Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Sorafenib; Vorinostat | 2019 |
Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma.
Topics: Acetylation; Animals; Carcinoma, Hepatocellular; Histone Deacetylases; Histones; Humans; Liver Neoplasms; Mice; Sorafenib; Thioredoxins; Vorinostat | 2023 |